Investment in Indian pharma company

The company is an established player in the generic oncology space, in the business for 17+ years. It is into manufacturing and marketing of chemotherapy, haematology, supportive care and NDDS niche products.

Main product offerings - chemotherapy range - Cisplatin, Carboplatin, Oxaliplatin, Doxorubicin, Etoposide, Cyclophosphamide, Ifosfamide,Flurouracil,Vincristine,Vinblastin,Leucovorin,Methotraxate, Paclitaxel, Docetaxel, Gemcitabine, Epirubicin, daunorubicin, Pemetrexid, Fulvestrant, PFS, Caecitabine, Imatinib, Erlotinib, Dasatinb

The company started as a drug marketing company and created a pan India presence in that space. Then it ventured into manufacturing and became an established player in the market. Its products are exported to 30 countries under emergency import permits and registration process is underway. The focus now is on creating a niche in NDDS and peptides. Also venturing into Liposomal delivery system and Nanoparticles.